Clinical and Biomarker Outcomes Expected to Be Reported in Q1 2026CAMBRIDGE, Mass., Dec. 22, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: ...
Digital twins began as static digital models used primarily for visualization and design. The review shows that they have ...
Treating accessibility as a core product requirement, not a compliance checkbox, is a competitive advantage that most of your ...
Some requests by reviewers to cite their own publications are coercive and can unnecessarily delay indexation and publication.
NeuroSense (NRSN) reported completion of the safety analysis from its proof-of-concept Phase 2, randomized, double-blind, placebo-controlled ...
AI design contest turns the future Forester into everything from a jungle tank to a rolling dessert, with fans now voting on ...
Background Global warming poses a significant threat to human mental health, with disproportionate effects on vulnerable and ...
Objective To determine whether a full-scale randomised control trial (RCT) assessing the efficacy and cost-effectiveness of a ...
National Law University, Jodhpur has invited submissions for an edited academic book titled “Emerging Frontiers in ...
Investing.com -- Neurosense Therapeutics Ltd (NASDAQ:NRSN) stock rose 5.5% on Monday after the company reported positive safety data for its Alzheimer’s disease treatment candidate.
Background In December 2022, California prohibited the sale of most flavoured tobacco products; however, limited data are ...
This research investigates the impact of Big Data Analytics (BDA) on organizational adaptability within the automotive sector in Egypt. The rapid technological advancements and increasing competition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback